<DOC>
	<DOCNO>NCT01282528</DOCNO>
	<brief_summary>To evaluate predictive value clinical , functional ( HAQ ) , laboratory US variable relation disease activity radiographic outcome patient RA start treatment Remicade 24 week .</brief_summary>
	<brief_title>Ultrasonographic Monitoring Response Infliximab Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>This open-lable , single arm study ultrasonographic monitoring response infliximab patient rheumatoid arthritis . Approximately 120 subject enrol . Subjects receive infliximab 3mg/kg intravenous infusion 0 , 2 , 6 week , repeat every 8 week 24 week . The efficacy assessment observe ACR response , HAQ , DAS28 , sharp score US assessment 0,2ï¼Œ6,14 , 22 , 24weeks ultrosonographic radiographic assessment conduct 0 , 6 , 24weeks . Subjects follow AEs SAEs 8 week follow last study treatment administration ( see Section 6 ) . The end study define time last subject complete 24 week visit .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1. age 1865 year , male female capable providing informed consent , must obtain prior studyrelated procedure . 2 . Those definitive diagnosis RA base criterion American College Rheumatology 1987 moderate severe disease ( DAS28 3.2 ) . 3 . Patients use oral corticosteroid , must stable dose prednisone 10mg/day equivalent least 4 week prior screen . If currently use corticosteroid patient must receive corticosteroid least 4 week prior screen . 4 . Patients use DMARDs , must stable dose least 12 week prior screen . If currently use DMARDs patient must receive DMARDs least 12 week prior screen . 5 . If use NSAIDs analgesic RA , must stable dose least 2 week prior first administration study agent . 1 . Patient known hypersensitivity human immunoglobulin proteins component infliximab . 2 . Patient suffers systemic inflammatory disease whose sign symptoms expect affect evaluation study drug . 3 . Patient history receive infliximab biologics . 4 . Patient stage IV RA . 5 . Patient live viral bacterial vaccination within 4 week study entry . 6 . Patient ever suffer chronic recurrent infection , include limited : chronic kidney infection , chronic thoracic cavity infection ( eg . bronchiectasis ) , nasosinusitis , recurrent urinary tract infection , open , drain dermal infect wound .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>